Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Dec;40(12):2882–2883. doi: 10.1128/aac.40.12.2882

Dialysis culture enables more accurate determination of MIC of benzylpenicillin for Borrelia burgdorferi than does conventional procedure.

S H Stiernstedt 1, B Wretlind 1
PMCID: PMC163640  PMID: 9124859

Abstract

A constant benzylpenicillin (penicillin G) concentration for determination of the MIC for strains of Borrelia burgdorferi was achieved by dialysis culture. The strains were grown in dialysis membrane bags with daily transfer to tubes with freshly added benzylpenicillin. The MICs decreased by one or several dilution steps compared with the conventional procedure.

Full Text

The Full Text of this article is available as a PDF (163.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asbrink E., Hovmark A., Hederstedt B. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Derm Venereol. 1984;64(6):506–512. [PubMed] [Google Scholar]
  2. Asbrink E., Hovmark A., Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):253–261. doi: 10.1016/s0176-6724(86)80128-6. [DOI] [PubMed] [Google Scholar]
  3. Asbrink E., Olsson I. Clinical manifestations of erythema chronicum migrans Afzelius in 161 patients. A comparison with Lyme disease. Acta Derm Venereol. 1985;65(1):43–52. [PubMed] [Google Scholar]
  4. Berger B. W., Kaplan M. H., Rothenberg I. R., Barbour A. G. Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol. 1985 Sep;13(3):444–449. doi: 10.1016/s0190-9622(85)70187-9. [DOI] [PubMed] [Google Scholar]
  5. Burgdorfer W., Barbour A. G., Hayes S. F., Benach J. L., Grunwaldt E., Davis J. P. Lyme disease-a tick-borne spirochetosis? Science. 1982 Jun 18;216(4552):1317–1319. doi: 10.1126/science.7043737. [DOI] [PubMed] [Google Scholar]
  6. Hansen K., Hovmark A., Lebech A. M., Lebech K., Olsson I., Halkier-Sørensen L., Olsson E., Asbrink E. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol. 1992 Aug;72(4):297–300. [PubMed] [Google Scholar]
  7. Johnson R. C., Kodner C., Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother. 1987 Feb;31(2):164–167. doi: 10.1128/aac.31.2.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johnson S. E., Klein G. C., Schmid G. P., Feeley J. C. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J Biol Med. 1984 Jul-Aug;57(4):549–553. [PMC free article] [PubMed] [Google Scholar]
  9. Karlsson M., Hovind-Hougen K., Svenungsson B., Stiernstedt G. Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis. J Clin Microbiol. 1990 Mar;28(3):473–479. doi: 10.1128/jcm.28.3.473-479.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lebech A. M., Hansen K. Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J Clin Microbiol. 1992 Jul;30(7):1646–1653. doi: 10.1128/jcm.30.7.1646-1653.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Luft B. J., Volkman D. J., Halperin J. J., Dattwyler R. J. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann N Y Acad Sci. 1988;539:352–361. doi: 10.1111/j.1749-6632.1988.tb31869.x. [DOI] [PubMed] [Google Scholar]
  12. Preac Mursic V., Wilske B., Schierz G., Pfister H. W., Einhäupl K. Repeated isolation of spirochetes from the cerebrospinal fluid of a patient with meningoradiculitis Bannwarth. Eur J Clin Microbiol. 1984 Dec;3(6):564–565. doi: 10.1007/BF02013623. [DOI] [PubMed] [Google Scholar]
  13. Preac-Mursic V., Wilske B., Schierz G. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):112–118. doi: 10.1016/s0176-6724(86)80110-9. [DOI] [PubMed] [Google Scholar]
  14. Schultz J. S., Gerhardt P. Dialysis culture of microorganisms: design, theory, and results. Bacteriol Rev. 1969 Mar;33(1):1–47. doi: 10.1128/br.33.1.1-47.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Steere A. C., Bartenhagen N. H., Craft J. E., Hutchinson G. J., Newman J. H., Rahn D. W., Sigal L. H., Spieler P. N., Stenn K. S., Malawista S. E. The early clinical manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):76–82. doi: 10.7326/0003-4819-99-1-76. [DOI] [PubMed] [Google Scholar]
  16. Steere A. C., Grodzicki R. L., Kornblatt A. N., Craft J. E., Barbour A. G., Burgdorfer W., Schmid G. P., Johnson E., Malawista S. E. The spirochetal etiology of Lyme disease. N Engl J Med. 1983 Mar 31;308(13):733–740. doi: 10.1056/NEJM198303313081301. [DOI] [PubMed] [Google Scholar]
  17. Steere A. C., Pachner A. R., Malawista S. E. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med. 1983 Dec;99(6):767–772. doi: 10.7326/0003-4819-99-6-767. [DOI] [PubMed] [Google Scholar]
  18. Stiernstedt G. Therapeutic aspects of Lyme borreliosis. Clin Dermatol. 1993 Jul-Sep;11(3):423–429. doi: 10.1016/0738-081x(93)90099-x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES